Novartis reports $56.7 billion in revenue for FY 2025, with net income of $14 billion and free cash flow of $17.7 billion.
Novartis AG posted a 10% year-over-year revenue increase to $56.7 billion in fiscal year 2025. The pharmaceutical company attributed growth to its focus on high-margin innovative treatments in oncology, neuroscience, and cardiovascular health.
Net income reached $14 billion, while free cash flow stood at $17.7 billion. The company’s debt-to-equity ratio was 0.8x as of December 2025, reflecting a balanced capital structure.
Novartis operates in 118 countries with a workforce of 77,000 employees, prioritizing prescription treatments for complex diseases.